Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: Analysis of a medical claims database

OBJECTIVE: To analyze the drug adherence rates and overall survival for in patients treated with arbiraterone acetate (AA) for castration-resistant prostate cancer (CRPC). METHODS: The database of the largest insurance company in Austria (Wiener Gebietskrankenkasse) was analyzed. Data on all CRPC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamad Al-Ali, Badereddin, Kramer, Gero, Madersbacher, Stephan, Berger, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486773/
https://www.ncbi.nlm.nih.gov/pubmed/27596230
http://dx.doi.org/10.1007/s00508-016-1067-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486773/
https://www.ncbi.nlm.nih.gov/pubmed/27596230
http://dx.doi.org/10.1007/s00508-016-1067-9

Ejemplares similares